Mutational signature analysis in non-small cell lung cancer patients with a high tumor mutational burden.

ABSTRACT:

Background

Lung cancer is the leading cause of cancer death worldwide. With the growing number of targeted therapies and the introduction of immuno-oncology (IO), personalized medicine has become standard of care in patients with metastatic disease. The development of predictive and prognostic biomarkers is of great importance. Mutational signatures harbor potential clinical value as predictors of therapy response in cancer. Here we set out to investigate particular mutational processes by assessing mutational signatures and associations with clinical features, tumor mutational burden (TMB) and targetable mutations.

Methods

In this retrospective study, we studied tumor DNA from patients with non-small cell lung cancer (NSCLC) irrespective of stage. The samples were sequenced

SUBMITTER: van den Heuvel GRM 

PROVIDER: S-EPMC8611965 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature